# Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events

> **NCT07694414** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Inge Marie Svane** · enrollment: 25 (estimated)

## Conditions studied

- Immune-Related Adverse Events

## Interventions

- **DRUG:** Rituximab (RTX)

## Key facts

- **NCT ID:** NCT07694414
- **Lead sponsor:** Inge Marie Svane
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-01
- **Primary completion:** 2028-08-01
- **Final completion:** 2028-12-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07694414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07694414, "Rituximab for Treatment of Checkpoint Inhibitor Induced Immune-related Adverse Events". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07694414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*